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Abstract
Background: Immune checkpoint inhibitors targeting PD-1/PD-L1 pathway demonstrated promising activities in
variety of malignancies, however little is known regarding their efficacy in adults aged ≥65 years.
Methods: We conducted a systematic review and a study-level meta-analysis to explore efficacy of ICIs based on
age, younger vs older than 65 years. We included in this analysis randomized controlled phase II or III studies in
patients with metastatic solid tumors that compared efficacy of PD-1 or PD-L1 inhibitors to a non-PD-1/PD-L1
inhibitor. Aggregated estimates of overall survival (OS) and progression-free survival (PFS) are based on random/
mixed effects (RE) models to allow for heterogeneity between the studies.
Results: Initial search identified 53 articles, 17 were randomized controlled trials that compared nivolumab,
pembrolizumab or atezolizumab to chemotherapy or targeted therapy. Only 9 trials reported hazard ratiios (HR) for
OS based on age and were included in this meta-analysis. Out of those studies seven reported HR for PFS but only
4 studies included subgroup-analysis based on age for PFS. The overall estimated random-effects HR for death was
0.64 with 95% CI of 0.54–0.76 in patients ≥65 years vs. 0.68 with 95% CI of 0.61–0.75 in patients < 65 years. The
overall estimated random-effects for HR for progression was 0.74 with 95% CI of 0.60–0.92 in patients ≥65 years
vs. 0.73 with 95% CI of 0.61–0.88 in patients < 65 years.
Conclusions: PD-1 (nivolumab and pembrolizumab) and PD-L1 (atezolizumab) inhibitors had comparable efficacy
in adults younger vs ≥ 65 years.
Background
The advent of Immune Checkpoint Inhibitors (ICIs)
changed the landscape of cancer treatment. Efficacy of
PD-1 and PD-L1 antibodies has been established in a
wide spectrum of solid and hematological malignancies.
[1–10] However, although cancer is predominantly a dis-
ease of older adults, the clinical efficacy of ICIs in this
population has not been specifically assessed. [11, 12]
Published literature suggests that aging-associated im-
mune changes may have an impact on the activity of
checkpoint inhibitors, including PD-1 and PD-L1 inhibi-
tors. [13] Cytotoxic CD8+ T cells in older adults were
found to have decreased TCR (T cell receptor) diversity,
reduced proliferative capacity, and increased sensitivity
to apoptotic signals compared to younger adults [14–16]
In some studies, aging was associated with decreased ex-
pression of CD28 on the surface of CD8+ T cells which
leads to decreased immune activation. [17–19] Expres-
sion of CD57, a marker of senescence, was found to be
increased on the surface of cytotoxic T cells of older
adults contributing to a diminished anti-tumoral im-
munogenic response. [20, 21] In addition, the levels of
perforin and granzyme, both essential for T cell’s cyto-
toxic activity, were lower in older adults compared to
younger individuals. [22] Interestingly, expression of PD-
1 was found to be increased on T cells of older adults
and its blockade did not restore T cell activity to the
same extent as in younger adults [22–24] Our under-
standing of the efficacy of PD-1 and PD-L1 antibodies in
older adults is limited due to underrepresentation of this
patient population in prospective clinical trials due to
concerns about the safety profile of the investigated
agents. [25] Consequently, we conducted a systematic
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review and a study-level meta-analysis to explore efficacy
of ICIs based on age, younger vs older than 65 years.
Methods
Search strategy and selection criteria
We performed a Pubmed database search from January
2009 to December 2016 using the medical subject head-
ings (MeSH) terms “pembrolizumab”, “nivolumab”, and
“atezolizumab”, the only Food and Drug Administration
(FDA) PD-1/PD-L1 ICIs approved at the time this
review was conducted. Search was done using the filter
“clinical trial”. The language was restricted to English.
We then performed additional searches of Web of
Science, ASCO meeting database, and ESMO meeting
database using the same terms. We reviewed the
“Drugs @FDA” database for randomized studies that
did not report number of patients aged ≥65 years en-
rolled on the trial or subgroup analysis for overall
survival (OS) by age (younger vs ≥ 65 years). Studies
meeting all of the following criteria were included: (1)
Randomized controlled phase II or III studies in
patients with metastatic solid cancer (2) Studies com-
paring efficacy of PD-1 or PD-L1 inhibitors to a non-
PD-1/PD-L1 inhibitor (3) Subgroup analysis for
survival using a hazard ratio (HR) based on age per-
formed in study or available in FDA label review. The
selection process is shown in Fig. 1. Studies involving
use of ICIs in hematologic malignancies were ex-
cluded from this meta-analysis.
Data extraction
Data extracted from eligible studies included: (1) Study
characteristics (first author, year of publication, study
name, design, phase, arms, National Clinical Trial
(NCT) number (2) Study population (total number of
randomized patients, total number in each arm, total
number of patients younger than 65 years, total number
of patients ≥65 years, number of patients younger than
65 years in each arm, number of patients ≥65 in each
arm, median age, age range, mean age (3) HR for OS
and for PFS (4) HR for OS and for PFS based on age
subgroups (younger vs ≥ 65 years). In the case of trials
that did not include survival subgroup analysis by age,
we reviewed each published trial’s supplement and the
FDA medical and statistical review available on the
“Drugs @FDA” database.
Statistical methods
Aggregated estimates of OS and progression-free sur-
vival (PFS) are based on random/mixed effects (RE)
models to allow for possible heterogeneity between the
studies. Forest plots were used to summarize and
visualize the HR with 95% confidence intervals (CI) for
each study and for the aggregated estimates from the RE
models. For studies reporting separate HR estimates for
65–75 and > 75 years, a combined estimate (≥ 65 years)
was created using random effects modeling, and the
combined estimate was used in the meta-analysis
for that study. Chi-squared p-values from Cochran’s
Q statistic assessed study heterogeneity. Analyses were
conducted using the “Metafor” package in R software
(Version 3.2.3, The R Foundation for Statistical Comput-
ing). Statistical significance is defined as P < 0.05; there
were no corrections for multiple comparisons.
Results
Search results and patient characteristics
We identified 53 studies that matched our basic
selection criteria of clinical trial involving one of the
FDA-approved PD-1 and PD-L1 agents. Thirty-six non--
randomized studies were excluded. Seventeen studies
were reviewed, 8 out of those 17 studies were excluded
as they did not contain OS subgroup analysis by age.
Final analysis included 9 studies: (6 phase 3 studies, 2
Fig. 1 Flow diagram of study inclusion
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phase 2 studies, and one phase 2/3 study). Among the 9
studies included in the analysis, 5 investigated nivolu-
mab, 2 investigated pembrolizumab, and 2 investigated
atezolizumab. Tumor types included metastatic non-
small cell lung cancer (NSCLC) in 5 trials, melanoma in
2, renal cell cancer in 1, and head and neck cancer in
one trial. Characteristics of each trial are presented in
Table 1. All studies reported a subgroup analysis based
on age except for the POPLAR study [26] for which HR
were obtained from the FDA medical review of atezoli-
zumab (Biologic License Application (BLA) 761,041).
Overall survival
Overall comparison
The endpoint of interest is overall survival in studies
comparing PD1/PDL1 therapy with chemotherapy/tar-
geted agents. The HR of the individual studies and the
combined results based on the random-effects models
are summarized in Fig. 2. The ratios presented compare
anti-PD1/PDL1 agents against chemo/targeted therapy
in the total population. The overall estimated, random-
effects HR is 0.69 with 95% CI of 0.63 to 0.74 (P < 0.
0001). Based on the selected trials, there is evidence of a
statistically significant, 31% reduction in the hazard of
death with PD1/PDL1 therapy compared with chemo/
targeted agents. The chi-squared test for heterogeneity
of studies was not significant (P = 0.52) suggesting that
the reported results of the individual trials are not sub-
stantially different from one another.
Survival according to age
The studies selected for this meta-analysis included a
total of 5458 patients. Age range of participants was 18–
89 years, and 2324 (42.57%) patients were older than
65 years. The random-effects estimate of the HR of
PD1/PDL1 agents compared to control therapy in
patients under age 65 is 0.68 (95% CI 0.61 to 0.75)
(Fig. 3a). For this subset, there was no evidence of
differences between the individual studies (chi-squared
P = 0.45) in the analysis. The random-effects estimate
of the HR for age 65 or older is 0.64 (95% CI 0.54 to
0.76) (Fig. 3b). For this subset, there was evidence of
differences in the HR between the individual studies
(chi-squared P = 0.03), suggesting considerable vari-
ability in the reported results among the studies. The
comparable hazard ratios for patients 65 and older
compared with those under 65 (0.64 vs. 0.68) as well
as the substantial overlap of the confidence intervals
of the two estimates would indicate that the effects of
therapy on survival did not vary for older or younger
adults (Table 2).
Progression-free survival
Overall progression-free survival
The endpoint of interest is progression-free survival in
studies comparing PD1/PDL1 therapy with chemother-
apy/targeted agents. Among studies included in this ana-
lysis, seven had HR for overall PFS including four that
reported HR for PFS according to age group. The HR
for PFS of the individual studies and the combined re-
sults based on the random-effects models are summa-
rized in Fig. 4. The overall estimated, random-effects HR
is 0.74 with 95% CI of 0.60 to 0.92 (P = 0.006). Based on
the selected trials, there is evidence of a statistically sig-
nificant, 26% reduction in the hazard of a PFS event with
PD1/PDL1 compared with chemo/targeted agents. The
Fig. 2 Forest plot for OS. Studies are listed on the left and HR with 95% CI are on the right. Box sizes are inversely proportional to the standard
error of the study; therefore, larger boxes indicate greater weight of the trial in the meta-analysis estimation. The HR from the Robert 01–201531
trial is lower than the others, but the weight of the trial is small and does not have great influence
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chi-squared test for heterogeneity of studies was highly
significant (P < 0.0001) suggesting that the reported HRs
of the individual trials are substantially different.
Progression-free survival according to age
The random-effects estimate of the HR of PD1/PDL1
compared with chemo/targeted therapy in patients
under age 65 is 0.73 (95% CI 0.61 to 0.88) (Fig. 5a), and
for patients age 65 or over the HR estimate is 0.74 (95%
CI 0.60 to 0.92) (Fig. 5b) For each subset of younger and
older patients, there was evidence of heterogeneity be-
tween the studies (chi-squared P = 0.03 and p = 0.05, re-
spectively), suggesting t there is considerable variability
in the reported results among the studies within each
subset. The equivalent HR estimates for the two age co-
horts along with the substantial overlap of the confi-
dence intervals of the two estimates, would indicate that
the effects of therapy upon PFS did not vary for older or
younger adults (Table 3).
Discussion
Increased age is associated with changes in the host im-
munity that could impact effectiveness of ICIs therefore
Fig. 3 Forest plot for OS for patients less than 65 years (A) and≥ 65 years (B). Studies are listed on the left and HR with 95% CI are on the right.
Box sizes are inversely proportional to the standard error of the study; therefore, larger boxes indicate greater weight of the trial in the
meta-analysis estimation
Table 2 Summary of HR for OS by Age
Age HR (95% CI)
Age < 65 years 0.68 (0.61 to 0.75)
Age≥ 65 years 0.64 (0.54 to 0.76)
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we aimed through this meta-analysis to evaluate the effi-
cacy of PD-1 and PD-L1 inhibitors in adults ≥65 years
with advanced solid tumors compared to those <
65 years. This meta-analysis suggests that the impact of
PD-1/PD-L1 inhibitors is comparable between adults
younger vs. older than 65 years for OS [HR 0.68 (CI
0.61–0.75) vs. 0.64 (CI 0.54–0.76)] and PFS [HR 0.73
(CI 0.61–0.88) vs. 0.74 (CI 0.60–0.92)]. The data were
not sufficient to draw any conclusions specific to pa-
tients ≥75 years. The number of patients older than
65 years enrolled in PD-1/PD-L1 studies is increased
compared to what is usually seen in oncology trials
but older adults remain under-represented in cancer
clinical trials. [25, 27, 28] This is particularly true for
individuals older than 75 years who constitute more
than 25% of newly diagnosed cases of cancer every
year. [11] Four of the trials included in this review
contained HR OS for patients ≥75 years. [4–6, 29]
However, out of 2093 individuals included in the ana-
lyzed trials only 10% (213) were ≥ 75 year. Accord-
ingly, data was not sufficient to draw any conclusions
specific to adults ≥75 years.
Few papers attempted to review this topic but only
one was performed at a meta-analysis level. [30] The
analysis performed by Nishijima et al..... was based on
9 studies, however among the trials included 4 were
with an anti-CTLA4 agents, therefore mixing two
classes of ICIs with different mode of action and effi-
cacy profile. Authors showed a comparable OS benefit
for ICIs in younger (HR 0.75, 95% CI 0.68 to 0.82)
and older adults (HR 0.73, 95% CI 0.62–0.78). It is
important to note the age cutoff was non-uniform
across selected studies (65–70 years). In addition, au-
thors did not show a statistically significant benefit in
terms of PFS for ICIs in adults ≥65 years (HR 0.77,
95% CI 0.58–1.01) vs. a significantly favorable HR in
patients < 65 years (HR 0.58, 95% CI 0.40–0.84). Betof
et al showed no significant difference in survival
benefit with PD1/PDL1 inhibitors according to age in
a retrospective analysis of patients treated in two
academic medical centers. [31] However, this analysis
included only patients with metastatic melanoma and
92.5% were treated with an anti-PD1 agent.
Although it was done at a study-level, our paper
constitutes the best level of evidence showing
comparable efficacy for checkpoint inhibitors targeting
checkpoint inhibitors in adults > 65 years compared
to younger patients. Studies included in this meta-
analysis, consistent with the majority of clinical trials
in oncology, used a numerical age cutoff. An arbitrary
age cutoff is not sufficient to characterize “older”
adults as aging is a highly variable physiological
process. Older individuals are not a homogenous
population, therefore measuring variables like func-
tional status and comorbidity is essential to determine
the physiologic “age” of an older adult [32]. In
addition, older individuals enrolled in clinical trials
tend to be adults aged 70–75 years, with good per-
formance status, and a low number of comorbid
medical conditions which does not represent the real-
life population of older adults with cancer who often
have functional limitations and multiple illnesses.
Fig. 4 Forest plot for PFS. Studies are listed on the left and HR with 95% CI are on the right. Box sizes are inversely proportional to the standard
error of the study; therefore, larger boxes indicate greater weight of the trial in the meta-analysis estimation
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Another limitation to our review is that data were ob-
tained partially from FDA BLA review of a particular
drug and not directly from the study itself as in the
case of POPLAR study. [26]
In conclusion, our meta-analysis showed that
improvement in survival associated with the use of
PD-1/PD-L1 inhibitors is consistent across age cut-off
of 65 years. More data are needed to understand
efficacy among those aged ≥75 years as well as
tolerance and toxicity of ICIs in older adults overall.
Further study is needed including comprehensive as-
sessment of outcomes of significant to older adults,
such as functional status and preservation throughout
therapy. Geriatric assessment and biomarkers of aging
and immune senesce will help to fully understand the
impact of ICIs in this growing subset of adults diag-
nosed with cancer.
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